Dr Robert Motzer presents his study of the results from the randomised, phase 3 CheckMate 914 trial. The study explores adjuvant nivolumab plus ipilimumab (NIVO+IPI) vs placebo (PBO) for localised renal cell carcinoma (RCC) at high risk of relapse after nephrectomy. 

CheckMate 914 key inclusion criteria included: radical or partial nephrectomy with negative surgical margins > 4 and ≤ 12 weeks before randomisation.

The results demonstrated that patients with localised RCC at high risk of relapse after nephrectomy did not meet the primary endpoint of DFS.